APA

Uckun F. M., Tibbles H., Erbeck D., Venkatachalam T. K. & Qazi S. (20070629). In vivo pharmacokinetics and toxicity of a novel hydrophilic oral formulation of the potent non-nucleoside reverse transcriptase inhibitor compound N'-[2-(2-thiophene)ethyl]-N'-[2-(5-bromopyridyl)]-thiourea (HI-443). : Arzneimittel-Forschung.

Chicago

Uckun Fatih M, Tibbles Heather, Erbeck Douglas, Venkatachalam Taracad K and Qazi Sanjive. 20070629. In vivo pharmacokinetics and toxicity of a novel hydrophilic oral formulation of the potent non-nucleoside reverse transcriptase inhibitor compound N'-[2-(2-thiophene)ethyl]-N'-[2-(5-bromopyridyl)]-thiourea (HI-443). : Arzneimittel-Forschung.

Harvard

Uckun F. M., Tibbles H., Erbeck D., Venkatachalam T. K. and Qazi S. (20070629). In vivo pharmacokinetics and toxicity of a novel hydrophilic oral formulation of the potent non-nucleoside reverse transcriptase inhibitor compound N'-[2-(2-thiophene)ethyl]-N'-[2-(5-bromopyridyl)]-thiourea (HI-443). : Arzneimittel-Forschung.

MLA

Uckun Fatih M, Tibbles Heather, Erbeck Douglas, Venkatachalam Taracad K and Qazi Sanjive. In vivo pharmacokinetics and toxicity of a novel hydrophilic oral formulation of the potent non-nucleoside reverse transcriptase inhibitor compound N'-[2-(2-thiophene)ethyl]-N'-[2-(5-bromopyridyl)]-thiourea (HI-443). : Arzneimittel-Forschung. 20070629.